Eli Lilly and Company
Compare market positioning with top industry peers
Explore Eli Lilly and
Core profile pages, annual revenue records, and related research hubs for this company.
Company History
Founded 1876 in Indianapolis, Indiana
In 1876, Colonel Eli Lilly, a veteran of the Civil War, was completely disgusted by the American pharmaceutical industry. It was totally unregulated; traveling salesmen sold toxic 'miracle cures' that frequently killed people. Lilly, a trained chemist, opened a small laboratory in Indianapolis with $1,400. He made a strict vow to only produce medicines that were exactly what they claimed to be, pioneered the use of gelatin capsules to hide the terrible taste of medicine, and built a massive empire based entirely on scientific legitimacy in an era of pure fraud.
Following his military service and early experiences in the apothecary trade, Lilly worked in various pharmaceutical and business ventures, eventually amassing enough capital to strike out on his own. In 1876, he founded Eli Lilly and Company in a small laboratory in Indianapolis, Indiana. His unyielding commitment to creating standardized, reliable, and scientifically verifiable medicines set an entirely new standard for the nascent pharmaceutical industry. Beyond his business acumen, Colonel Lilly was known as a tireless civic leader and philanthropist, dedicating significant time and resources to improving the city of Indianapolis and fostering a corporate culture that valued employee welfare and community engagement. His legacy extends far beyond the company he built, influencing the broader trajectory of American industrial philanthropy.
Colonel Eli Lilly founds the company in Indianapolis.
Lilly helps commercialize insulin at industrial scale, shaping its long-term diabetes identity.
The company expands through antibiotics and broader prescription medicines.
Lilly introduces Humulin, one of the first recombinant DNA human insulin products.
David A. Ricks becomes Chair, President, and CEO.
Mounjaro receives U.S. approval for type 2 diabetes, beginning a major growth cycle.
Zepbound receives U.S. approval for chronic weight management.
Lilly reports $65.179B in 2025 revenue and $20.640B in net income.
Lilly acquired Loxo Oncology in January 2019 for approximately $8 billion to acquire a precision oncology platform built around the concept of targeting specific genomic alterations in cancer regardless of tumor type. Loxo had pioneered the development of selective kinase inhibitors designed to minimize off-target effects while achieving exceptional on-target potency against genomically defined cancer populations. The acquisition was intended to accelerate Lilly's transformation into a precision medicine oncology leader at a time when the company recognized that undifferentiated cytotoxic chemotherapy partnerships were not a sustainable competitive strategy in oncology.
Lilly acquired Morphic Therapeutic in August 2024 for approximately $3.2 billion to access the company's integrin inhibitor platform, which includes MORF-057, an oral small-molecule inhibitor of α4β7 integrin with potential in inflammatory bowel disease including Crohn's disease and ulcerative colitis. The inflammatory bowel disease market represents a high-value segment that Lilly had not previously addressed with differentiated proprietary assets, and Morphic's oral small-molecule approach offered a potential advantage over existing large-molecule biologics like vedolizumab that require infusion or injection. The acquisition reflected Lilly's strategy of using its strong balance sheet and cash generation to acquire late-stage development assets that can be accelerated through its global clinical and commercial infrastructure.
Lilly acquired POINT Biopharma Global Inc. In October 2023 for approximately $1.4 billion to acquire the company's radioligand therapy (RLT) platform and manufacturing infrastructure. Radioligand therapies, which combine tumor-targeting molecules with radioactive isotopes to deliver targeted radiation to cancer cells, represent a rapidly advancing area of oncology following the commercial success of Novartis's Lutathera and Pluvicto. The acquisition gave Lilly access to POINT's proprietary radiopharmaceutical manufacturing facilities—a specialized industrial capability that is scarce globally—as well as a pipeline of RLT candidates in clinical development for prostate cancer and other malignancies.
Lilly acquired Prevail Therapeutics in January 2021 for approximately $1.04 billion upfront plus contingent payments to access the company's gene therapy platform targeting neurological diseases, particularly Parkinson's disease and related alpha-synucleinopathies. Prevail's lead asset, PR001, is an AAV9-based gene therapy designed to deliver a functional copy of the GBA1 gene to neurons, targeting the subset of Parkinson's disease patients with GBA1 mutations who face faster disease progression. The acquisition represented Lilly's first significant investment in the gene therapy space and reflected the company's strategy of expanding its neuroscience portfolio beyond small molecules and antibodies.
Since its establishment in 1876, Eli Lilly and Company expanded from an early-stage venture into a recognized leader in Pharmaceuticals, obesity medicines, diabetes care, oncology, immunology, and neuroscience, overcoming key market challenges.
Over its history, Eli Lilly and Company executed decisive strategic pivots toward scalable monetization and digital distribution, securing its current market leadership.
By continually modernizing operations and embracing workflow automation, Eli Lilly and Company maintains resilience through changing technological and economic cycles.